Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02615249 · ClinicalTrials.gov registry record · Phase 2
Clinical Evaluation of Metal Panel Allergens: Dose Response Study
A Phase 2 study, sponsored by Allerderm.
- Completed
- Registry status
- Phase 2
- Development phase
- 122
- Enrollment target
NCT02615249: Completed Phase 2 study, sponsored by Allerderm.
NCT02615249 is a Phase 2 study that has completed, run by Allerderm. The registered enrollment target is 122 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02615249, a Phase 2 study, has completed, sponsored by Allerderm.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 122 participants
- Enrollment target
Study Summary
48-hour application of metal allergen patches to test for potential allergic responses.
Primary Outcome
Allergen patch test sites were scored at Visit 3 (day 3-4) Visit 4 (day 7-8) Visit 5 (day 10-14) and Visit 6 Day 19-23). Determination of positive or negative test response for each allergen dose was assessed by the investigator following the final visit.
Interventions
- BIOLOGICAL Metal Allergen Epicutaneous Patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2016-12-05 |
| Est. Completion | 2019-07-15 |
| Phase | Phase 2 |
What the finished NCT02615249 record still lists
NCT02615249 is an interventional study that assigns participants to a tested intervention. The registered 122 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which Metal Allergen Epicutaneous Patch is the first listed.
NCT02615249 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02615249 about?
NCT02615249 is a clinical study titled "Clinical Evaluation of Metal Panel Allergens: Dose Response Study". 48-hour application of metal allergen patches to test for potential allergic responses.
What is the current status of trial NCT02615249?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 122 participants. The study started on 2016-12-05. Estimated completion is 2019-07-15.
What interventions are being tested in trial NCT02615249?
The interventions under investigation include: Metal Allergen Epicutaneous Patch (BIOLOGICAL).
Who is sponsoring clinical trial NCT02615249?
This trial is sponsored by Allerderm, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02615249's enrollment target sits among peer trials
122 565th of 2000 higher than 1,434 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03363373 · 122 participants · Phase 2
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
- NCT03463954 · 122 participants · NA
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors
- NCT04503265 · 122 participants · Phase 1
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
- NCT04700527 · 122 participants · Phase 1
The Effects of SCFA Supplementation in Subjects Receiving Abdominopelvic RT: A Randomized Controlled Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI